Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis

• Shuo Yang ,

  Roles Conceptualization

  * E-mail: 30968738@qq.com

  Affiliation Department of Endocrinology and Metabolism, The People’s Hospital of China Medical University, The People’s Hospital of Liaoning Province, Shenyang, Liaoning Province, P.R.China

  https://orcid.org/0000-0001-5253-9188

  ⨯
• Wei He,

  Roles Conceptualization

  Affiliation Department of Endocrinology and Metabolism, The People’s Hospital of China Medical University, The People’s Hospital of Liaoning Province, Shenyang, Liaoning Province, P.R.China

  ⨯
• Lu Zhao,

  Roles Conceptualization

  Affiliation Department of Endocrinology and Metabolism, The People’s Hospital of China Medical University, The People’s Hospital of Liaoning Province, Shenyang, Liaoning Province, P.R.China

  ⨯
• Yaochuan Mi

  Roles Conceptualization

  Affiliation Department of Endocrinology and Metabolism, The People’s Hospital of China Medical University, The People’s Hospital of Liaoning Province, Shenyang, Liaoning Province, P.R.China

  ⨯